Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
暂无分享,去创建一个
Xiao Chen | Pan Chen | Changxi Wang | Xiaoman Liu | Longshan Liu | Kejing Tang | Min Huang | Binbin Lv
[1] Qingnan He,et al. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method , 2021, Frontiers in Pharmacology.
[2] E. Porrini,et al. Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update , 2021, Nephron.
[3] G. Aithal,et al. Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[4] E. Björnsson,et al. Drug-Induced Liver Injury - Types and Phenotypes. , 2019, The New England journal of medicine.
[5] T. Karlsen,et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. , 2019, Journal of hepatology.
[6] L. Butani. Immunosuppressive Medications in Kidney Transplantation , 2018, Adolescents with Chronic Kidney Disease.
[7] Jacqueline Corrigan-Curay,et al. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. , 2018, JAMA.
[8] Q. Shi,et al. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status , 2017, International journal of toxicology.
[9] C. Stephens,et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. , 2016, Journal of hepatology.
[10] G. Danan,et al. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease , 2016, Drug Safety.
[11] S. Abid,et al. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats , 2016, Journal of Physiology and Biochemistry.
[12] William M. Lee,et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. , 2015, Gastroenterology.
[13] I. Mahmood. Prediction of drug clearance in children: a review of different methodologies , 2015, Expert opinion on drug metabolism & toxicology.
[14] R. Fontana,et al. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. , 2014, Journal of hepatology.
[15] P. Kes,et al. Rescue therapy with sirolimus in a renal transplant recipient with tacrolimus-induced hepatotoxicity , 2013, Renal failure.
[16] S. Min,et al. Conversion of Twice‐Daily Tacrolimus to Once‐Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] G. Gores,et al. Frequency, clinical presentation, and outcomes of drug‐induced liver injury after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[18] M. Schuemie,et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. , 2010, British journal of clinical pharmacology.
[19] Ethan M Balk,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.
[20] Y. Mizuguchi,et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. , 2008, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[21] Sh Zhongyang,et al. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. , 2007, Transplantation proceedings.
[22] E. Björnsson,et al. Long‐term follow‐up of patients with mild to moderate drug‐induced liver injury , 2007, Alimentary pharmacology & therapeutics.
[23] P. Kuo,et al. One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] R. Andrade,et al. Outcome of acute idiosyncratic drug‐induced liver injury: Long‐term follow‐up in a hepatotoxicity registry , 2006, Hepatology.
[25] J. Chapman,et al. The natural history of chronic allograft nephropathy. , 2003, The New England journal of medicine.
[26] S. Jensik,et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1 , 2003, Transplantation.
[27] G. Anderson. Children Versus Adults: Pharmacokinetic and Adverse‐Effect Differences , 2002, Epilepsia.
[28] E. Wijdicks. Neurotoxicity of immunosuppressive drugs , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[29] Joshua Miller,et al. A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .
[30] J. Pirsch,et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.